Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer
Immunocheckpoint inhibitors (ICI), such as nivolumab, atezolizumab and pembrolizumab, have shown significant clinical efficacy in advanced non-small cell lung cancer (NSCLC) [1 –3]. One emerging biomarker for predicting response to ICI therapy is tumor mutational burden (TMB) [4]. Lung cancer patients with high-TMB (≥ 10 mutations per megabase, mut/MB) showed significantly longer progression-free survival (PFS) when treated with nivolumab plus ipilimumab than with chem otherapy (median PFS 7.2 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Shaowei Lan, Hui Li, Ying Liu, Lixia Ma, Xianhong Liu, Yan Liu, Shi Yan, Ying Cheng Source Type: research